AMR101, which contains ≥96% eicosapentaenoic acid (EPA), ethyl ester, and no docosahexaenoic acid (DHA), reduced TG (relative to placebo, at 4-g/day dose) by 33% in patients with hypertriglyceridaemia [135] and by 21.5% in patients with mixed dyslipidaemia also receiving statin [136], significantly reduced non-HDL-C, apoB and VLDL-C and did not increase LDL-C [135, 136]. The gene discussed is APOB; the disease is hypertriglyceridemia.